The Great Digital Shift: Where Synthetic Biology, Biomanufacturing, and Biopharma Combine
In this article on synbiobeta.com, the partnership between Riffyn and Novozymes is highlighted as an example of how R&D organizations are transforming their R&D processes.
Tim Gardner is the Founder and the CEO of Riffyn. He was previously Vice President of Research & Development at Amyris, where he led the engineering of yeast strain and processes technology for large-scale bio-manufacturing of renewable chemicals. Tim has been recognized for his pioneering work in Synthetic Biology by Scientific American, the New Scientist, Nature, Technology Review, and the New York Times. He also served as an advisor to the European Union Scientific Committees and the Boston University Engineering Alumni Advisory Board. Tim enjoys hockey, running, mountain biking, and being beaten by his sons in almost everything.